Narcolepsy, Type 2 (Q41285): Difference between revisions

From determinar.ia.br - Determine suas informações
Changed an Item
Changed an Item
 
(5 intermediate revisions by the same user not shown)
Property / CURIE
 
CID11:7A20.1
Property / CURIE: CID11:7A20.1 / rank
 
Normal rank
Property / Canary Token
 
dki-india-7A20.1
Property / Canary Token: dki-india-7A20.1 / rank
 
Normal rank
Property / Verification Status
 
Concluído
Property / Verification Status: Concluído / rank
 
Normal rank
Property / Knowledge Architect
 
Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank
 
Normal rank
Property / Collection date
 
13 August 2026
Timestamp+2026-08-13T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / Collection date: 13 August 2026 / rank
 
Normal rank
Property / Linked ICD 10
 
Property / Linked ICD 10: G47.4 / rank
 
Normal rank

Latest revision as of 07:24, 13 August 2026

Type 2 narcolepsy is a disorder of excessive sleepiness characterised by daily periods of irrepressible need to sleep or daytime lapses into sleep and abnormal manifestations of REM sleep as demonstrated by multiple sleep latency test (MSLT/PSG) findings in the context of normal hypothalamic hypocretin (orexin) signaling. That is, cerebrospinal fluid (CSF) hypocretin determinations are > 110 picograms per milliliter. Cataplexy is not present. The disorder is not attributable to another disease of the nervous system or other medical condition. Note: A definitive diagnosis requires daily periods of irrepressible need to sleep or daytime lapses into sleep and multiple sleep latency test/polysomnography (MSLT/PSG) findings characteristic of narcolepsy. There should be no evidence of cataplexy or CSF hypocretin deficiency (if testing is performed).
Language Label Description Also known as
default for all languages
7A20.1
    English
    Narcolepsy, Type 2
    Type 2 narcolepsy is a disorder of excessive sleepiness characterised by daily periods of irrepressible need to sleep or daytime lapses into sleep and abnormal manifestations of REM sleep as demonstrated by multiple sleep latency test (MSLT/PSG) findings in the context of normal hypothalamic hypocretin (orexin) signaling. That is, cerebrospinal fluid (CSF) hypocretin determinations are > 110 picograms per milliliter. Cataplexy is not present. The disorder is not attributable to another disease of the nervous system or other medical condition. Note: A definitive diagnosis requires daily periods of irrepressible need to sleep or daytime lapses into sleep and multiple sleep latency test/polysomnography (MSLT/PSG) findings characteristic of narcolepsy. There should be no evidence of cataplexy or CSF hypocretin deficiency (if testing is performed).

      Statements

      CID11:7A20.1
      0 references
      dki-india-7A20.1
      0 references
      Concluído
      0 references
      13 August 2026
      0 references
      0 references